Abbott Launches Lingo, First Over-the-Counter Continuous Glucose Monitor for Health and Wellness in the US

Launch Date:
Abbott's Lingo, a non-prescription continuous glucose monitor (CGM) for health and wellness, was launched in the US on September 5, 2024.

Target Audience:
Lingo is designed for individuals aged 18 and older who do not take insulin and are interested in improving their overall health and wellness.

Pricing:
Lingo is priced at $49 for a 14-day sensor, $89 for two sensors, or $249 for six sensors, making it competitive with Dexcom's Stelo CGM.

Features:
The Lingo system includes a biosensor and a mobile app that provides real-time glucose data, personalized insights, and customized coaching to help users create healthy habits and improve their metabolism.

Market Potential:
The launch of Lingo and similar over-the-counter CGMs opens a new market, potentially targeting 96 million people with prediabetes in the US, with Abbott expecting Lingo to be a "meaningful contributor" to sales in 2025 and beyond.

Competition:
Dexcom's Stelo CGM, also an over-the-counter device, is a competitor in this new market, with Dexcom expecting to reach $40 million in sales related to Stelo by the end of 2024.